gilead-sciences
(2)Company
Company
Health
The $4.9 Billion Signal
Forty Seven sold a simple idea with enormous consequences: persuade the immune system to eat cancer. Gilead paid $4.9 billion for the possibility. The trials delivered a harder lesson.
forty-seven-inc · immuno-oncologyRead →
Health
Arcellx
Arcellx rebuilt a crucial part of CAR-T therapy with a compact synthetic binder. Its lead treatment is now under FDA review - and the company behind it has become part of Gilead's Kite.
cell-therapy · car-tRead →